Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial

[1]  E. Bonfá,et al.  Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis , 2021, Lupus.

[2]  M. Gatto,et al.  Lupus nephritis: clinical presentations and outcomes in the 21st century , 2020, Rheumatology.

[3]  E. Frangou,et al.  2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[4]  B. Yoo,et al.  Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine , 2019, Lupus.

[5]  K. Kawahata,et al.  Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV , 2018, Arthritis Research & Therapy.

[6]  Agnes B. Fogo,et al.  Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.

[7]  G. Chusney,et al.  Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  Ji‐Won Kim,et al.  Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine , 2017, The Journal of Rheumatology.

[9]  Michael Doherty,et al.  The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies , 2017, Rheumatology.

[10]  L. Chatzi,et al.  Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece , 2017, Annals of the rheumatic diseases.

[11]  C. Ponticelli,et al.  Hydroxychloroquine in systemic lupus erythematosus (SLE) , 2017, Expert opinion on drug safety.

[12]  B. Rovin,et al.  A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. , 2016, Kidney international.

[13]  L. Langman,et al.  Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis , 2016, Arthritis care & research.

[14]  Maria V Ghetu,et al.  Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management. , 2016, American family physician.

[15]  B. Rovin,et al.  Current and Emerging Therapies for Lupus Nephritis. , 2016, Journal of the American Society of Nephrology : JASN.

[16]  M. Clark,et al.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. , 2015, Seminars in nephrology.

[17]  M. Marmor,et al.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.

[18]  A. Edefonti,et al.  Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  J. Reveille,et al.  Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort , 2012, Lupus.

[20]  S. Leeder,et al.  A systematic review of epidemiological studies on the association between smokeless tobacco use and coronary heart disease , 2011 .

[21]  G. Zilleruelo,et al.  Three decades of progress in treating childhood-onset lupus nephritis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[22]  D. Gladman,et al.  The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[23]  M. Urowitz,et al.  SLEDAI-2K for a 30-day window , 2010, Lupus.

[24]  J. Reveille,et al.  Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. , 2009, Arthritis and rheumatism.

[25]  E. Silverman,et al.  Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. , 2008, The Journal of pediatrics.

[26]  J. Reveille,et al.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.

[27]  G. Ruiz-Irastorza,et al.  Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus , 2006, Lupus.

[28]  N. Ilowite,et al.  Systemic lupus erythematosus in children and adolescents. , 2006, Pediatrics in review.

[29]  E. Bonfá,et al.  Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. , 2001, The Journal of rheumatology.

[30]  C. Lam,et al.  Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease , 2000, Lupus.

[31]  I. Bruce,et al.  The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.

[32]  H. Hodis,et al.  The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[33]  A D GUNN,et al.  Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.